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Abstract
Background: Tophi contribute to musculoskeletal disability, joint damage and poor health-related quality of life in
people with gout. The aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous
disease in people with gout.
Methods: Participants (n = 1778) with gout fulfilling the 1977 American Rheumatism Association (ARA) classification
criteria, who were recruited from primary and secondary care, attended a detailed study visit. The presence of
palpable tophi was recorded. SLC2A9 rs11942223, ABCG2 rs2231142 and ABCG2 rs10011796 were genotyped. Data
were analysed according to tophus status.
Results: Compared to participants without tophi, those with tophi were older, had longer disease duration and
higher serum creatinine, and were more likely to be of Māori or Pacific (Polynesian) ancestry. SLC2A9 rs11942223 was
not associated with tophi. However, the risk alleles for both ABCG2 single nucleotide polymorphisms (SNPs) were
present more frequently in those with tophi (OR (95% CI) 1.24 (1.02–1.51) for rs2231142 and 1.33 (1.01–1.74) for
rs10011796, p < 0.05 for both). The effect of rs2231142 was limited to participants of Māori or Pacific ancestry (OR 1.
50 (1.14–1.99), p = 0.004), with a significant effect observed in those of Western Polynesian ancestry only (OR 1.71 (1.
07–2.72), p = 0.017). The rs10011796 risk allele was strongly associated with tophi in the Western Polynesian group
(OR 3.76 (1.61–8.77), p = 0.002), but not in the Eastern Polynesian group (OR 0.87 (0.52–1.46), p = 0.60) nor in the
non-Polynesian group (OR 1.16 (0.81–1.66), p = 0.32). The ABCG2 associations persisted in the Western Polynesian
group after adjusting for serum urate, creatinine, and disease duration, and when including both ABCG2 variants in
the regression models.
Conclusions: Variation in ABCG2 function may play a role in the development of tophaceous disease in some
populations with high prevalence of severe gout.
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Background
The gouty tophus consists of monosodium urate (MSU)
crystal deposits surrounded by chronic granulomatous
inflammatory tissue [1]. In people with gout, tophi con-
tribute to musculoskeletal disability, joint damage and
poor health-related quality of life, and are associated
with increased risk of mortality [2–5]. Typically, tophi
present as subcutaneous nodules many years after initial
presentation with acute inflammatory flares [6]. Al-
though advanced age, kidney disease and diuretic use
have been reported to be risk factors for development of
tophi (reviewed in [7]), few studies have systematically
examined the features associated with tophaceous
disease.
In the last decade, there has been major progress in
understanding the genetic basis of hyperuricaemia and
gout. Variants in two genes, ABCG2 and SLC2A9, are
consistently associated with hyperuricaemia and preva-
lent gout in many different populations [8–10].* Correspondence: n.dalbeth@auckland.ac.nz1Department of Medicine, Faculty of Medical and Health Sciences, University
of Auckland, 85 Park Rd, Grafton, Auckland, New Zealand
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Aotearoa New Zealand has a high prevalence of gout,
with early onset, severe disease in Māori and Pacific
people [11, 12]. The SLC2A9 rs11942223 risk allele is
strongly associated with prevalent gout in Māori and
Pacific people living in Aotearoa New Zealand [13]. In
contrast, the ABCG2 rs2231142 risk allele (Q141K) has
population-specific effects in Polynesian people, with a
strong association with gout in people of Western Poly-
nesian (Tonga, Samoa, Niue and Tokelau) ancestry, but
a weak effect in people of Eastern Polynesian (New Zea-
land Māori and Cook Island Māori) ancestry [14].
Although the association with gout is well-established
in many populations, it is unclear whether variants in
these genes also contribute to phenotypic differences in
people with gout. We have previously reported that a
non-synonymous SLC2A9 Arg265His variant is associ-
ated with tophi in New Zealand Māori with gout [15],
and a Taiwanese study has reported an association be-
tween ABCG2 Q141K and tophi in both Han Chinese
and Taiwanese aboriginal people with gout [16]. The
aim of this study was to examine the role of SLC2A9
and ABCG2 variants in tophaceous disease in people
with gout.
Methods
People with gout were recruited into the study, Genetics
of Gout in Aotearoa, from primary and secondary care
in Aotearoa New Zealand (n = 1778) [10]. The study was
designed to identify genetic and clinical factors associ-
ated with gout. All participants in this analysis fulfilled
the 1977 American Rheumatism Association (ARA) pre-
liminary gout classification criteria [17]. The New Zea-
land Multi-Region Ethics Committee granted ethical
approval (MEC/05/10/130) and all patients provided
written informed consent.
All participants attended a study visit, which included
a detailed clinical assessment. This included recording of
age of onset of the first presentation with gout, flare fre-
quency in the previous year (self-reported), medications,
physical examination of weight and height, and serum
creatinine testing. The presence of palpable tophi was
assessed by experienced research assistants with training
in the clinical assessment of gout. The highest recorded
serum urate concentration was obtained from commu-
nity electronic laboratory records. Presence of comorbid
conditions (specifically cardiac disease, hypertension and
type 2 diabetes mellitus) was recorded and verified using
the electronic medical record. The estimated glomerular
filtration rate (eGFR) was calculated using the modifica-
tion of diet in renal disease formula [18].
SLC2A9 rs11942223, ABCG2 rs2231142 and ABCG2
rs10011796 single nucleotide polymorphisms (SNPs)
were genotyped using TaqMan SNP genotyping assay
technology (Applied Biosystems) [10]. SLC2A9
rs11942223 and ABCG2 rs2231142 were selected as
variants consistently associated with gout in many popu-
lations, including Polynesian populations (reviewed in
[9]). ABCG2 rs10011796 was selected as an additional
gout-associated ABCG2 SNP [8], noting that this SNP
has also been associated with allopurinol response in a
USA study population [19]. The linkage disequilibrium
(r2) was <0.11 between the two ABCG2 SNPs for all an-
cestral groups. Risk allele positivity was analysed for the
ABCG2 SNPs. However, owing to the high prevalence of
the risk allele at SLC2A9, particularly in Polynesian
people, minor allele (T) positivity was analysed instead.
Data were analysed in SPSS v22 (SPSS Inc., Chicago, IL,
USA). Clinical and genetic features were analysed
according to tophus status (tophi vs no tophi). Pearson’s
chi-squared test (categorical variables) and the two-
sample t test (continuous variables) were used to compare
the two groups. P < 0.05 was considered significant for this
analysis and was not corrected for multiple testing due to
prior evidence of genetic effects in gout and tophus. For
the detailed ABCG2 analysis, logistic regression was
performed on the presence/absence of the risk allele with
tophus status, adjusted by potential confounders. Polynes-
ian ancestry was separated into Western Polynesian
(Tonga, Samoa, Niue or Tokelau) and Eastern Polynesian
(Māori or Cook Island Māori) [14]. In the case of mixed
Polynesian ancestry with Māori (n = 29), patients were
analysed as Māori (Eastern Polynesian) as recommended
by the New Zealand Ministry of Health.
Results
Clinical features
Of the 1778 participants with gout, there were 627
(35.3%) participants with at least one palpable tophus at
the time of study examination. Compared to participants
without tophi, those with tophi were older, had longer
disease duration and higher serum creatinine, and were
more likely to be of Māori or Pacific (Polynesian) ances-
try (Table 1). Participants with tophi also reported more
frequent gout flares and greater use of colchicine, pred-
nisone, non-steroidal anti-inflammatory drugs and
urate-lowering therapy.
In the 851 participants of Māori or Pacific ancestry,
there were 339 participants (39.8%) with at least one
palpable tophus at the time of the study examination. In
this group, those with tophi were more likely to be male
and had longer disease duration (Table 1). In the 927
participants who were not of Polynesian ancestry, there
were 288 participants (31.1%) with at least one palpable
tophus at the time of the study examination. In this
group, those with tophi were older, and had longer dis-
ease duration, higher serum creatinine and higher ever-
recorded serum urate concentration (Table 1).
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Genetic analysis
There was no difference in the frequency of the minor
(protective) allele for SLC2A9 rs11942223 between the
group with tophi and the group without tophi for the en-
tire sample set (p = 0.14) (Table 2 and Additional file 1).
Similar findings were observed in the participants of
Māori or Pacific ancestry and in the participants who were
not of Polynesian ancestry (Table 2 and Additional file 1).
In contrast, in the entire group, the risk alleles for
both ABCG2 SNPs were present more frequently in
those with tophi (odds ratio (OR) (95% CI) 1.24 (1.02–
1.51) for rs2231142 and 1.33 (1.01–1.74) for rs10011796,
p < 0.05 for both (Table 2 and Additional file 1)). Ana-
lysis of ABCG2 risk allele frequencies according to an-
cestry demonstrated that the effect of rs2231142 was
limited to participants of Māori or Pacific ancestry (OR
1.50 (1.14–1.99), p = 0.004) (Table 2 and Additional file
1), with a significant effect observed in those of Western
Polynesian ancestry (OR 1.71 (1.07–2.72), p = 0.017) but
not in Eastern Polynesian ancestry (OR 1.28 (0.84–1.96),
p = 0.25) (Table 3 and Additional file 1). The rs10011796
risk allele was also strongly associated with tophi in the
Western Polynesian group (OR 3.76 (1.61–8.77), p =
0.002), but not in the Eastern Polynesian group (OR 0.87
(0.52–1.46), p = 0.60) nor in the non-Polynesian group
(OR 1.16 (0.81–1.66), p = 0.32) (Table 3 and Additional
file 1). The ABCG2 associations persisted in the Western
Polynesian group when including the other ABCG2 vari-
ant in the regression model; the age and sex adjusted
OR for rs2231142 was 1.64 (1.101–2.65), p = 0.045, and
for rs10011796 it was 3.60 (1.53–8.44), p = 0.003.
The ABCG2 associations also persisted in the Western
Polynesian group after adjusting for age, sex, highest
recorded serum urate, serum creatinine and disease
Table 1 Clinical characteristics of participants























Male sex, n (%) 100 955 (83.0%) 542 (86.4%) 0.06a 100 541 (84.7%) 245 (85.1%) 0.87a 100 414 (80.9%) 297 (87.6%) 0.01a
Age, years 99.5 57 (14) 58 (14) 0.52b 100 62 (14) 64 (13) 0.02b 100 52 (13) 53 (13) 0.50b
Duration of gout,
years




95.9 4.8 (8.4) 7.9 (11.9) <0.001b 95.4 3.8 (7.5) 6.2 (10.3) <0.001a 96.5 6.0 (9.2) 9.4 (13.0) <0.001b
Māori or Pacific
ancestry, n (%)
100 512 (44.5%) 339 (54.1%) <0.001a
Body mass index,
kg/m2
98.4 32.9 (8.05) 33.0 (7.66) 0.78b 98.5 30.31 (7.19) 29.86 (5.50) 0.35b 98.4 36.13 (7.90) 35.72 (8.20) 0.47b
Cardiac disease, n (%) 99.4 353 (30.9%) 221 (35.3%) 0.06a 99.7 203 (31.9%) 116 (40.3%) 0.01a 99.2 150 (29.6%) 105 (31.1%) 0.66a
Diabetes, n (%) 98.6 217 (19.2%) 138 (22.2%) 0.14a 99.4 92 (14.5%) 51 (17.7%) 0.22a 97.8 125 (25.1%) 87 (26.0%) 0.76a
Alcohol intake,
servings per week
98.3 6.1 (10.8) 5.4 (9.3) 0.15b 99.4 6.9 (9.9) 6.6 (9.9) 0.62b 97.9 5.1 (11.8) 4.4 (8.5) 0.31b
Diuretic use, n (%) 100 285 (24.8%) 173 (27.6%) 0.06a 100 157 (24.6%) 85 (29.5%) 0.06a 100 128 (25.0%) 88 (26.0%) 0.57a
Colchicine use, n (%) 94.4 547 (51.2%) 406 (67.3%) <0.001a 97.1 275 (44.6%) 168 (59.7%) <0.001a 91.4 272 (53.1%) 238 (70.2%) <0.001a
Prednisone use, n (%) 95.1 433 (40.1%) 322 (53.0%) <0.001a 97.5 214 (34.5%) 141 (49.6%) <0.001a 92.5 219 (47.6%) 181 (55.9%) 0.02a
NSAID use, n (%) 97.0 877 (78.6%) 499 (81.1%) 0.21a 98.2 470 (75.2%) 224 (78.8%) 0.23a 95.8 400 (83.2%) 275 (83.4%) 0.97a
Urate-lowering
therapy, n (%)
99.5 829 (72.5%) 541 (86.4%) <0.001a 99.5 441 (69.6%) 244 (84.7%) <0.001a 99.5 388 (76.2%) 297 (87.9%) <0.001a
Creatinine at time of
recruitment, mmol/L
98.9 111 (57) 120 (57) <0.001b 99.1 109 (45) 121 (57) <0.001b 98.1 114 (68) 120 (57) 0.22b
eGFR, mL/min/
1.73 m2
98.7 65 (20) 61 (22) <0.001b 99.1 64 (20) 59 (22) <0.001b 98.1 65 (21) 63 (21) 0.09b
Serum urate at time
of recruitment,
mmol/L
100 0.42 (0.11) 0.41 (0.12) 0.76b 100 0.40 (0.11) 0.40 (0.11) 0.59b 100 0.44 (0.11) 0.42 (0.13) 0.08b
Highest recorded
serum urate, mmol/L
100 0.55 (1.11) 0.55 (0.13) 0.97b 100 0.49 (0.13) 0.52 (0.12) <0.001b 100 0.62 (1.65) 0.57 (0.12) 0.59b
Unless specified, data are presented as mean (SD). aP value from Pearson’s chi-squared test. bTwo-sided p value from two-sample t test with equal variances. NSAID
non-steroidal anti-inflammatory drugs, eGFR estimated glomerular filtration rate
He et al. Arthritis Research & Therapy  (2017) 19:43 Page 3 of 6
duration; the multivariate OR for rs2231142 was 1.66
(1.01–2.75), p = 0.048, and for rs10011796 was 3.23
(1.35–7.76), p = 0.009 (Table 4). Similar results for both
ABCG2 SNPs were observed in participants of Māori or
Pacific ancestry with at least three Polynesian grandpar-
ents, with generally higher ORs (Table 5).
Discussion
This study provides evidence that variation in ABCG2
function may play a role in the development of tophac-
eous disease in some populations with high prevalence
of severe gout. This effect appears to be independent of
other risk factors such as serum urate concentrations or
disease duration.
High prevalence of gout has been reported in indigen-
ous Māori and in Pacific people residing in Aotearoa
New Zealand, with contemporary rates of 11.7% in
Māori men and 13.5% in Pacific men, compared to 3.7%
in European men [11]. Our study has shown higher
prevalence of tophaceous disease in people with gout of
Māori or Pacific ancestry. Consistent with prior studies
[6, 20, 21], we have also demonstrated that disease dur-
ation is associated with tophaceous disease in people
with gout. Although serum urate concentrations were
associated with tophaceous disease in participants of
non-Polynesian ancestry, this association was not ob-
served in the participants of Māori or Pacific ancestry.
This study has also highlighted the impact of disease in
patients with tophi, with more frequent flares and
greater use of anti-inflammatory therapy, compared to
people with gout without tophi.
The key finding of this study is the ancestry-specific
differences in the association between ABCG2 variants
and tophaceous disease in people with gout. In particu-
lar, the associations with the ABCG2 SNPs were ob-
served consistently only in the Western Polynesian
ancestral group. Association of a similar effect size
between rs2231142 (Q141K) and tophi has been
reported in both Han and aboriginal Taiwanese people
with gout (OR 1.51 and 1.50, respectively, for the 141 K
allele) [16]. Other data also support the ancestry-specific
effects of ABCG2 in gout; we have previously reported
that compared to people without gout, the rs2231142
risk allele (141 K) is associated with susceptibility to
gout in New Zealanders of European and Western Poly-
nesian ancestry, but not in those of Eastern Polynesian
ancestry [14]. Importantly, the frequency of the
rs2231142 risk allele is substantially higher in people of
Western Polynesian ancestry, compared with the other
ancestral groups: in a prior case-control study compar-
ing people with gout with control participants with gout
[14], the minor allele frequency in people unaffected by
gout was 27.5% in Western Polynesians, 9.0% in Eastern
Polynesians and 12.6% in Europeans; the minor allele
frequency in people with gout was 51.9% in Western
Polynesians, 10.7% in Eastern Polynesians and 24.2% in
Europeans.
We also report a novel association between another
ABCG2 SNP rs10011796 and tophi in people with gout
who are of Western Polynesian ancestry. This ancestry-
specific association between tophi and rs10011796 was
independent of rs2231142 (Q141K). Together with
Table 3 SLC2A9 and ABCG2 genotype frequency in Polynesian ancestry subsets according to tophus status
Eastern Polynesian ancestry Western Polynesian ancestry









SLC2A9 rs11942223 protective allele (C) present, n (%) 100 24 (8.2%) 17 (9.8%) 0.56 100 12 (5.4%) 8 (4.8%) 0.79
ABCG2 rs2231142 risk allele (T) present, n (%) 100 70 (24.1%) 50 (28.9%) 0.25 100 150 (67.9%) 130 (78.3%) 0.023
ABCG2 rs10011796 risk allele (T) present, n (%) 98.3 242 (84.9%) 142 (83.0%) 0.60 98.2 185 (85.6%) 157 (95.7%) 0.001
aP value from Pearson’s chi-squared test
Table 2 SLC2A9 and ABCG2 genotype frequency in the entire group and in ancestral groups according to tophus status
























100 204 (17.7%) 94 (15.0%) 0.14 100 168 (26.3%) 69 (24.0%) 0.45 100 36 (7.0%) 25 (7.4%) 0.85
ABCG2 rs2231142 risk
allele (T) present, n (%)
100 483 (42.0%) 296 (47.2%) 0.033 100 263 (41.2%) 116 (40.3%) 0.80 100 220 (43.0%) 180 (53.1%) 0.004
ABCG2 rs10011796 risk
allele (T) present, n (%)
97.9 917 (81.7%) 529 (85.6%) 0.039 97.5 490 (78.9%) 230 (81.3%) 0.41 98.2 427 (85.2%) 299 (89.3%) 0.092
aP value from Pearson’s chi-squared test
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rs2231142, this SNP has been associated with allopurinol
response in a USA study population of people with gout
[19]. Of note, the strong effect of rs10011796 on allopurinol
response in the USA study was attenuated after adjusting
for ancestry, further suggesting ancestry-specific effects
[19]. The ancestry-specific effects at ABCG2 may relate to
different haplotypic backgrounds between the Western
Polynesian, European and Eastern Polynesian populations.
This possibility could be evaluated by specific resequencing
of this locus in people of Polynesian ancestry.
The mechanisms of association between ABCG2 and
tophaceous disease in people with gout are currently un-
clear. Both SLC2A9 and ABCG2 are associated with
hyperuricaemia in the general population, and the lack
of an observed association between tophaceous disease
and SLC2A9 rs11942223 suggests that the association
between ABCG2 and tophaceous disease in people with
gout are not entirely due to effects on serum urate concen-
trations. This conclusion is further supported by the per-
sistent associations with ABCG2 after adjusting for serum
urate and disease duration. The ABCG2 risk alleles have
been associated with allopurinol resistance, and it is pos-
sible that these variants lead to relative hyperuricaemia
even with urate-lowering therapy, increasing the risk of
tophaceous disease [19, 22]. ABCG2 (also known as breast
cancer resistance protein (BCRP)) is ubiquitously expressed
(reviewed in [23]), and it is also possible that altered
ABCG2 function may regulate other factors contributing to
tophus formation, such as promotion of crystal formation
or the inflammatory response to deposited crystals.
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aAdjusted by ancestry for analysis in “All participants”











Allelic OR (95% CI) P Allelic OR (95% CI) P Allelic OR (95% CI) P
rs2231142 T Unadjusted 1.77 (1.30–2.42) <0.001 1.65 (0.98–2.78) 0.059 1.77 (1.10–2.87) 0.020
Adjusted for age and sex 1.76 (1.28–2.42) <0.001 1.60 (0.95–2.69) 0.077 1.86 (1.14–3.04) 0.013
Adjusted for age, sex, highest
recorded urate, serum creatinine
and disease duration
1.63 (1.17–2.28) 0.004 1.29 (0.74–2.26) 0.37 1.70 (1.01–2.86) 0.045
rs10011796 T Unadjusted 1.73 (1.04–2.88) 0.036 0.90 (0.47–1.69) 0.73 4.61 (1.73–12.26) 0.002
Adjusted for age and sex 1.74 (1.04–2.91) 0.034 0.91 (0.48–1.73) 0.78 4.58 (1.72–12.22) 0.002
Adjusted for age, sex, highest
recorded urate, serum creatinine
and disease duration
1.72 (1.002–2.95) 0.049 0.89 (0.45–1.77) 0.75 3.90 (1.42–10.68) 0.008
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Conclusions
In our study, the association between ABCG2 variants
and tophaceous disease persisted in people with gout of
Western Polynesian ancestry even after adjusting for po-
tential confounders such as highest recorded urate, dis-
ease duration and serum creatinine. These findings raise
the possibility that the relationship between ABCG2 and
tophaceous disease are independent of the effects of pro-
longed hyperuricaemia.
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